Toward a Quantitative Understanding of Aficamten Clinical Pharmacology: Population Pharmacokinetic Modeling

ABSTRACT Aficamten is a next‐in‐class, cardiac myosin inhibitor in development as a potential chronic oral treatment for patients with hypertrophic cardiomyopathy (HCM). A population pharmacokinetic (PK) model was developed using data from nine clinical studies to characterize aficamten PK and ident...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Donghong Xu, Hanbin Li, Stephen B. Heitner, Daniel L. Jacoby, Stuart Kupfer, Polina German, Justin Lutz
Format:	Artigo
Jezik:	Inglês
Izdano:	Wiley 2025-12-01
Serija:	CPT: Pharmacometrics & Systems Pharmacology
Teme:	cardiovascular disease clinical trials inhibitors modeling population pharmacokinetics simulation
Online dostop:	https://doi.org/10.1002/psp4.70099
Oznake:	Označite Brez oznak, prvi označite!